RTN4R and cancer: Furthermore, given the intrinsic property of angiogenesis-targeting heterodimers to distinguish between activated and quiescent endothelial cells, the use of NGR heterodimers radiolabeled with alpha or beta emitter therapeutic isotopes is emerging as a potentially new approach to targeted cancer therapy.